Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 17, 2022

Study Completion Date

June 17, 2022

Conditions
Solid Tumors
Interventions
DRUG

Topotecan and Pazopanib

Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.

Trial Locations (10)

Unknown

Alberta Children's Hospital, Calgary

BC Children's Hospital, Vancouver

CancerCare Manitoba, Winnipeg

Janeway Child Health Centre, St. John's

IWK Health Centre, Halifax

McMaster Children's Hospital, Hamilton

Children's Hospital, London Health Sciences Centre, London

Children's Hospital of Eastern Ontario (CHEO), Ottawa

Hospital for Sick Children, Toronto

CHU St. Justine Hopital, Montreal

All Listed Sponsors
collaborator

C17 Council

OTHER

lead

The Hospital for Sick Children

OTHER

NCT02303028 - Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours | Biotech Hunter | Biotech Hunter